EMA official says AstraZeneca shots have good risk-benefit profile for over 60s
Reuters
Published Jun 13, 2021 20:22
MILAN (Reuters) - The head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca (NASDAQ:AZN)'s coronavirus vaccine had a favourable risk-benefit profile for all age groups and particularly for those aged over 60.
Italian newspaper La Stampa earlier quoted European Medicines Agency (EMA) task force chief Marco Cavaleri as saying countries should avoid giving the vaccine to people aged over 60 in addition to younger age groups, amid fears over fears over very rare blood clotting and as alternative vaccines become available.
"Unfortunately my words have not been interpreted correctly in a recent interview with La Stampa," Cavaleri said in a statement to Reuters. The AstraZeneca shot "maintains a favourable benefit risk profile in all ages but particularly in the elderly above 60," he said.
The EMA's position is that the AstraZeneca shot is safe and can be used for all age groups over 18. However several European Union member states have restricted its use to those in the age range 50 to 65, due to very rare cases of blood clotting, mainly among young people.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.